

Who Benefits from Enhanced Breast Imaging?

2023 Multidisciplinary Cancer Update

Brett T. Roberts, M.D.

October 7, 2023

Disclosures

None

Overview

- ACR/SBI screening recommendations
- 3D Tomosynthesis
- MRI
- Ultrasound
- **Contrast enhanced mammography**

Overview

- ACR
 - American College of Radiology
- SBI
 - Society of Breast Imaging

ACR/SBI Screening recommendations

- Average risk women
 - Once a year screening mammogram starting at age 40
 - 40% reduction in mortality from breast cancer

ACR/SBI High Risk Recommendations

- **All women should have their risk for breast cancer assessed by age 25**

High Risk Classification

- Genetics based
 - Including untested first degree relatives
- Calculated lifetime risk 20% or more
 - **Tyrer Cuzick model**
 - Gail Model, BRCAPRO, etc.

ACR/SBI High Risk Recommendations

- Genetics based or increased calculated lifetime risk
 - **Annual mammography beginning at age 25 to 30**
 - **3D tomosynthesis**
 - **Annual breast MRI beginning at age 25 to 30**

ACR/SBI High Risk Recommendations

- History of chest radiation before age 30
 - Annual mammography beginning at 25 or 8 years after therapy (whichever is later)
 - Annual breast MRI beginning at age 25 to 30

ACR/SBI High Risk Recommendations

- Personal history of breast cancer
 - Dense breasts (any age)
 - Or diagnosed before age 50
 - **Annual breast MRI**
 - **Bilateral**

ACR/SBI High Risk Recommendations

- Personal history of ADH or lobular neoplasia
 - **Annual breast MRI should be considered**

ACR/SBI High Risk Recommendations

- Dense breasts
 - If supplemental screening is desired, annual breast MRI with IV contrast should be considered
 - If MRI not possible, consider contrast mammography or ultrasound

ACR/SBI High Risk Recommendations

- **Consider** contrast mammography or screening ultrasound for those who cannot undergo MRI

Contrast Mammography

- Patients that qualify for but cannot undergo MRI
 - CDR, sensitivity, and specificity similar to MRI

3D Tomosynthesis

- Increases breast cancer detection rate
 - Extra 0.2-2.7 cancers per 1000 women
- Decreases recall rate
 - Approximately 15% - 36.8%
- Improves positive predictive value for biopsies
 - (PPV3) 50% over 2D
- Decreases BIRADS 3 follow-up by 50%

Screening Breast Ultrasound

- Increases cancer detection rate
 - 2-4 mammographically occult cancers per 1000 women
- But high false positive rate
 - **Positive predictive value from biopsies (PPV 3) ~8%**

Screening Breast MRI

- Increases cancer detection rate
 - **Examples:**
 - Study 1: Additional 15 cancers in 1000 women
 - Study 2: Additional 16 cancers in 1000 women
 - Interval cancer rate went to zero
- **PPV3 rate is comparable to mammography**

Breast MRI Indications


- ACR Appropriateness Criteria
 - Screening
 - New breast cancer
 - Extent of disease
 - 3-9% of women will have a contralateral breast cancer
 - 12-30% have occult ipsilateral disease
 - Preoperative systemic therapy
 - Lumpectomy positive margins
 - Breast cancer recurrence
 - Metastatic cancer of unknown primary

Contrast Enhanced Mammography

- Case
 - High risk screening
 - Dense breast tissue
 - Minimal background parenchymal enhancement
 - Normal exam


RCC



LCC







[
H
M
] RMLO]


[
H
M
] LMLO]















Contrast Enhanced Mammography

- Case
 - High risk screening
 - Extremely dense breast tissue
 - History of left breast cancer, post mastectomy
 - Minimal background parenchymal enhancement
 - Normal exam


[R] [C] RCC




[R] [2] RMLO



C
N
R
RCC



C
N
R
RMLO




Contrast Enhanced Mammography

- Case
 - High risk screening
 - Dense breast tissue
 - Minimal background parenchymal enhancement
 - Bilateral retropectoral silicone implants
 - Right 12:00 axis focal non-mass enhancement spanning 1.2 cm
 - Recommended ultrasound followed by ultrasound biopsy
 - Biopsy was benign, but marker in different location
 - Fibroadenomatoid change, focal chronic inflammatory infiltrate
 - Opted for 6 month follow-up right CEM


[C
H
M] RCC








[C
H
M] RCCID



[C
H
M] RCCID








[M] LCC [F]






[C] LCCID [H]
[M]




[C] LCCID [H]
[M]








RT BREAST 12:00 4 cm fn ANTIRADIAL



RT BREAST 12:00 4 cm fn ANTIRADIAL

high


S




4.0

-4.0
cm/s


RT BREAST 12:00 4 cm fn ANTIRADIAL



RT BREAST 12:00 4 cm fn RADIAL



RT BREAST 12:00 4 cm fn RADIAL




RT BREAST 12:00 4 cm fn ANTIRADIAL

[M] [H] [C]
RCC





[M] [H] [C]
RMLID




Contrast Enhanced Mammography


- Case
 - Average risk screening
 - Dense and complex breast tissue
 - History of 6 benign breast biopsies
 - Moderate background parenchymal enhancement
 - Right breast medial region posterior depth non-mass enhancement
 - Biopsy proven benign fibroadenomatoid changes and stromal fibrosis





[12
12 RMLO]



[12
12 RMLO]









Contrast Enhanced Mammography



- Miscellaneous cases

[2.2] RMLO [2.2]


[2.2] LMLO [2.2]









RCC




RCC






ESR
RMLO





ESR
RMLO





Upright Mammogram Biopsy, Standard Technique

- Case
 - Screen detected right breast calcifications
 - History of bilateral breast reduction and lift
 - Upright mammogram biopsy
 - Lateral to medial needle direction














Prone Mammogram Biopsy, Lateral Arm

- Case
 - Patient presents from an outside institution
 - Right breast lower inner quadrant calcifications
 - Superficial in location
 - Surgical biopsy was recommended








TEC
R






C




Prone Mammogram Biopsy, Lateral Arm

- Case
 - Screen detected superficial right breast finding
 - Focal asymmetry with indistinct margins (possible interspersing fat)
 - Sonographic correlate, but better seen by mammogram
 - Prone mammogram biopsy
 - Too superficial for standard technique
 - Lateral arm biopsy
 - Benign vascular lesion
 - Capillary hemangioma vs angiolipoma








RT BREAST 4:00 6 cm fn ANTIRADIAL

S



0.0

+Dist

0.96 cm

XDist

0.43 cm

2.0


3.0




RT BREAST 4:00 6 cm fn ANTIRADIAL

H
60
59

F












[Z] RCC



[Z] RML





TEC
R



Case

Negative screening mammogram



Screening MRI same month


IDC, triple negative



[G] RCC




RMLO












RT 10:00 6 cm fn RADIAL





RT 10:00 6 cm fn RADIAL





Case

Patient presented with right breast lump
IDC, not well seen by 2D mammography


Outside case, tomo not available

Only C-view

MRI shows extent of disease


Treatment: Mastectomy, chemotherapy, radiation

RMLO




RMLO

C-View




RCC






C-View

RCC









Sources

Monticciolo DL, Newell MS, Moy L, et al. Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR. 2017; J Am Coll Radiol 2018;15:408-414.

Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol. 2013;14(7):583-9.

Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014;311(24):2499-507.

Skaane P, Bandos AI, Gullien R, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology. 2013;267(1):47-56.

Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299(18):2151-63.

Hooley RJ, Greenberg KL, Stackhouse RM, Geisel JL, Butler RS, Philpotts LE. Screening US in patients with mammographically dense breasts: initial experience with Connecticut Public Act 09-41. Radiology. 2012;265(1):59-69.

Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394-404.

Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S. Supplemental Breast MR Imaging Screening of Women with Average Risk of Breast Cancer. Radiology. 2017;283(2):361-70.

Hendrick ER, Helvie MA. United States Preventive Services Task Force Screening Mammography Recommendations: Science Ignored. AJR 2011;196:W112-W116.

Sources

Monticciolo DL, Newell MS, Moy L, et al. Breast Cancer Screening in Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. Published May 5, 2023. <https://doi.org/10.1016/j.jacr.2023.04.002>

Coldman A, Phillips N, Wilson C, et al. Pan-Canadian study of mammography screening and mortality from breast cancer. J Natl Cancer Inst 014;106:dju261-dju.

Duffy SW, Tabár L, Chen H-H, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 2002;95:458-69.

Hendrick RE, Helvie MA. United States Preventive Services Task Force screening mammography recommendations: science ignored. AJR Am J Roentgenol 2011;196:W112-6.

Tabár L, Vitak B, Chen TH-H, et al. Swedish Two-County Trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011;260:658-63.

Tabár L, Yen AM-F, Wu WY-Y, et al. Insights from the breast cancer screening trials: how screening affects the natural history of breast cancer and implications for evaluating service screening programs. Breast J 2014;21:13-20.

Facts

Women 40-44 twice as likely to get cancer than 35-39

Almost as many women in their 40's diagnosed as those in their 50's

More than 75% of women in their 40's have no family history or other factors

40% years of life saved are for women in their 40's

ACS predicts their guidelines would allow 6540 extra deaths

USPSTF allows 13770 deaths a year

SBI/ACR/ACS/USPSTF all agree the most lives and years saved is from screening at 40

Facts

Annual vs biennial screening saves 40% more lives and 40% more years

Biennial has 81% benefit, meaning if you had a population large enough to save 100 lives you would only save 81 (CISNET)

1 2-view mammogram is about 2 months background radiation

Yaffe et al. Health Reports, Vol. 26 (12), 9-15; 2015